Sestina Bio to develop digital cell engineering platform

By The Science Advisory Board staff writers

October 15, 2020 -- Sestina Bio, a new company developing an automated synthetic biology platform, has been launched with seed funding. Sestina also is the first company to be launched from the Foresite Labs incubator.

Funding was provided by Foresite Capital, General Inception, and OMX Ventures and will be used to develop digital cellular engineering and phenotyping platforms and support initial product development.

The platforms will include instruments for single-cell genome editing, tools for single-cell phenotyping, and closed-loop machine learning-driven design and control of experiments, which cumulatively will form the next generation of automated synthetic biology toolkits.

Riffyn, Imperial College partner to speed up synthetic biology research
Riffyn and Imperial College in London have formed a partnership aimed at bringing Riffin's Nexus process data system to the public synthetic biology research...
Hexagon Bio secures $47M to advance drug discovery platform
Hexagon Bio has closed $47 million in series A financing to advance its drug discovery capabilities on its fungal genomics-based platform.
Making CRISPR safer with new enzyme-based prediction tool
A new technique will help scientists choose the best available gene editing option for any given indication, making CRISPR technology safer, cheaper,...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter